Aziyo Biologics, Inc.
http://www.aziyo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aziyo Biologics, Inc.
Three Chinese Biotechs Bag Late-Stage VC/PE Funding In February
Evopoint, I-Mab Biopharma (Hangzhou) and MAXVAX extended their funding with series E and C rounds, respectively, in February, amid signs that biotech investor sentiment in China may be recovering.
Watch Out GSK! China’s Homegrown Shingles Vaccine Set To Soar
Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.
Gene Therapy, RNA-Focused Biotechs Lead China December Fundraising
Venture capital and private equity firms pumped a combined $102m into seven Chinese biotechs in major deals announced during December.
The Quality Lowdown: The Warning Letter Monsoons That Might Follow The Inspection Drought
Selective whistleblower allegations, investigative reports hint at drug GMP issues awaiting US FDA inspection resumption; GSK sotrovimab EUA gets root cause provision; API GMP compliance work acknowledged; Aziyo recalls bone matrix associated with tuberculosis outbreak, and other matters in this latest update.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Biomaterials
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- CorMatrix Cardiovascular, Inc.
- HighCape Partners
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice